The manufacturer, Novo Nordisk, has reported that during the first three months of this year, the number of people signing up for the weight reduction medication Wegovy in the US increased fivefold to over 25,000 every week.
The spike is a result of the medicine’s intense demand, which has been praised as innovative together with its sister diabetes medication, Ozempic, and has made Novo Nordisk one of the most valuable corporations in Europe.
However, the pharmaceutical behemoth is now under further pressure as the US scrutinizes the exorbitant cost of these medications and competitors Eli Lilly launches competing products.
The company claimed it had lowered pricing in the US in the first three months of the year in a quarterly update for investors.
